David Pernock Insider Trading $EGRX EAGLE PHARMACEUTICALS, INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David Pernock.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David Pernock. David Pernock is Chairman and CEO in Fibrocell Science, Inc. ($FCSC) and Chief Executive Officer in Fibrocell Science, Inc. ($FCSC) and Director in Fibrocell Science, Inc. ($FCSC) and Director in EAGLE PHARMACEUTICALS, INC. ($EGRX) and Pres & Chief Operating Officer in EAGLE PHARMACEUTICALS, INC. ($EGRX) and Pres. & Chief Comm. Officer in EAGLE PHARMACEUTICALS, INC. ($EGRX).
David Pernock in EAGLE PHARMACEUTICALS, INC.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of David Pernock: Pres & Chief Operating Officer, Pres. & Chief Comm. Officer, Director
Holdings: 54,625 shares
Current Value: $3,793,160
Latest Transaction: Feb 04 2021
$EGRX Market Capitalization: $1.09B
$EGRX Previous Close: $69.44
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of David Pernock in EAGLE PHARMACEUTICALS, INC.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 04 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Grant | A | 0.00 | 9,700 | 0 | 54,625 | 44.9 K to 54.6 K (+21.59 %) |
| Jan 26 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Payment of Exercise | F | 47.70 | 1,892 | 90,248 | 44,925 | 46.8 K to 44.9 K (-4.04 %) |
| Jan 11 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Payment of Exercise | F | 50.97 | 906 | 46,179 | 46,817 | 47.7 K to 46.8 K (-1.90 %) |
| Jan 07 2021 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres & Chief Operat ... | Payment of Exercise | F | 50.02 | 2,088 | 104,442 | 47,723 | 49.8 K to 47.7 K (-4.19 %) |
| Jan 27 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Payment of Exercise | F | 57.98 | 1,793 | 103,958 | 49,811 | 51.6 K to 49.8 K (-3.47 %) |
| Jan 07 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 59.80 | 51,000 | 3,049,545 | 51,000 | |
| Jan 07 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Payment of Exercise | F | 57.38 | 904 | 51,872 | 51,604 | 52.5 K to 51.6 K (-1.72 %) |
| Jan 07 2020 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Grant | A | 0.00 | 21,500 | 0 | 52,508 | 31 K to 52.5 K (+69.34 %) |
| Jan 25 2019 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 42.40 | 46,600 | 1,975,840 | 46,600 | |
| Jan 25 2019 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Grant | A | 0.00 | 20,900 | 0 | 31,008 | 10.1 K to 31 K (+206.77 %) |
| Jan 25 2019 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Payment of Exercise | F | 41.33 | 858 | 35,461 | 10,108 | 11 K to 10.1 K (-7.82 %) |
| Jan 09 2018 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 0.00 | 30,000 | 0 | 30,000 | |
| Jan 09 2018 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 59.14 | 50,000 | 2,957,000 | 50,000 | |
| Jan 09 2018 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Grant | A | 0.00 | 10,000 | 0 | 10,966 | 966 to 11 K (+1,035.20 %) |
| May 19 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 79.69 | 255 | 20,321 | 966 | 711 to 966 (+35.86 %) |
| May 16 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 82.24 | 200 | 16,448 | 711 | 511 to 711 (+39.14 %) |
| Mar 21 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 83.98 | 61 | 5,123 | 511 | 450 to 511 (+13.56 %) |
| Mar 10 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Buy | P | 77.84 | 450 | 35,028 | 450 | 0 to 450 |
| Jan 06 2017 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Pres. & Chief Comm. ... | Option Exercise | A | 84.92 | 90,000 | 7,642,800 | 90,000 | |
| Jan 05 2016 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 86.15 | 15,000 | 1,292,250 | 15,000 | |
| Apr 22 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 59.31 | 15,000 | 889,650 | 15,000 | |
| Apr 10 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 46.81 | 10,000 | 468,100 | 10,000 | |
| Apr 10 2015 | EGRX | EAGLE PHARMACEUTIC ... | Pernock David | Director | Option Exercise | A | 46.81 | 10,000 | 468,100 | 10,000 |
Page: 1